Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19339911 | 1.00 | DPP4 (0.42) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5500605 | 1.00 | DPP4 (0.42) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14979667 | 1.00 | DPP4 (0.42) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14538332 | 1.00 | DPP4 (0.42) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23214633 | 0.84 | GRIN2D (0.41) | ARG1KMT2A | |
| SCHEMBL14979674 | 0.83 | CHRNB2 (0.39) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14467426 | 0.83 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30571958 | 0.83 | CHRNB2 (0.39) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17341180 | 0.82 | CHRNB2 (0.37) | DPP4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17715154 | 0.82 | NR1H2 (0.43) | DPP4ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239153-A1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | Gilead Pharmasset LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2935279-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2907816-A1 | Condensed imidazolylimidazoles as antiviral compounds | Gilead Pharmasset LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | DPP4 136/4885CHRNB2 4874/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.